To facilitate access to the market it should be possible to authorise a group of biocidal products as a biocidal product family. Biocidal products within a biocidal product family should have similar uses and the same active substances. Variations in the composition or the replacement of non-active substances should be specified, but may not adversely affect the level of risk or significantly reduce the efficacy of the products.
◷
New version applies from 25/04/2014.
113 provisions change.
Later versions: 20/11/2019, 29/03/2021, 10/06/2021, 15/04/2022, 26/05/2024, 11/06/2024, 15/06/2026, 19/08/2026.
Recital 36 changes in this version: compare with the current text.